Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | APLNR | P35414 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12389091 | 0.90 | SRD5A1 (0.48) | RAB9AALDH1A1APLNR | |
| SCHEMBL12365327 | 0.88 | SLC6A3 (0.46) | MEN1KMT2AMAPK14MAPTNPC1 | |
| SCHEMBL12365683 | 0.87 | BRD4 (0.39) | MEN1KMT2AMAPK14MAPTNPC1 | |
| SCHEMBL12389839 | 0.87 | KMT2A (0.44) | KMT2AMAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL12389781 | 0.86 | MAPK14 (0.48) | MAPK14MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL12365301 | 0.86 | MAPK14 (0.43) | MEN1KMT2AMAPK14MAPTALDH1A1 | |
| SCHEMBL12365758 | 0.85 | MEN1 (0.40) | MEN1KMT2AMAPK14MAPTNPC1 | |
| SCHEMBL12365832 | 0.85 | MAPK14 (0.44) | MEN1KMT2AMAPK14MAPTNPC1 | |
| SCHEMBL12389756 | 0.85 | MAPT (0.45) | MEN1KMT2AMAPK14MAPTRAB9A | |
| SCHEMBL12365662 | 0.84 | SLC6A3 (0.36) | MEN1KMT2AMAPK14MAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110207729-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207729-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | HTR5A, HTR2A, HTR1E | MEN1 4480/4885KMT2A 2505/4885MAPK14 3304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.